JANNSEN Sciences officially opened its new manufacturing building in Ringaskiddy today, creating an additional 200 full-time jobs.
The company, which is part of the Johnson & Johnson family, has operated a biopharmaceutical supply chain facility on its 40-hectare site in Ringaskiddy since 2005.
The project, which has taken two years to complete, employed approximately 450 people.
The official opening ceremony for the facility was attended by Tánaiste Simon Coveney, Kathy Wengel, Executive Vice-President and Chief Global Supply Chain Officer, Johnson & Johnson and Martin Shanahan, chief executive of IDA Ireland.
Speaking at the event, An Tánaiste Simon Coveney, said: "I’m delighted to attend the official opening of Janssen’s new manufacturing building, which marks the company’s ongoing commitment to Ireland and patients around the world.
"The life sciences industry makes a hugely significant contribution to the national economy in terms of jobs and exports.
"In 2018 alone, 33% of Ireland’s total exports were pharmaceutical and medical products, with Johnson & Johnson featuring as one of our single largest exporters."
The Ringaskiddy expansion will allow Janssen to meet demand worldwide for biologic medicines in the areas of multiple myeloma, rheumatoid arthritis and Crohn's disease, something that
Kathy Wengel, Executive Vice President and Chief Global Supply Chain Officer, Johnson & Johnson is immensely proud of: "Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions that advance how medicines are manufactured so that we can be at the forefront of treating, preventing, intercepting and curing some of the world’s most devastating and complex diseases."